BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Core Insights - BriaCell Therapeutics Corp. is set to present strong evidence of immune system engagement and anti-cancer activity of its Bria-OTS+ platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 7-9, 2025 [1][2][3] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [6] - The Bria-OTS+ platform is an advanced version of Bria-OTS™, designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules [4] Upcoming Presentation Details - The poster presentation titled "Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance" will take place on November 7, 2025, at the Prince George ABC Exhibit Halls [2] - The presentation will showcase extensive data on immune system activation and cytotoxicity, validating the potential of the personalized cancer immunotherapy platform [3] Clinical Development - Lead candidates Bria-BRES+ (for breast cancer) and Bria-PROS+ (for prostate cancer) have completed GMP manufacturing and are expected to enter Phase 1/2a clinical studies [4] - Bria-PROS+ is supported by a $2 million National Cancer Institute (NCI) Small Business Innovative Research (SBIR) award, announced on August 25, 2025 [4] Strategic Importance - The Bria-OTS+ platform represents a novel, cost-effective, off-the-shelf cancer therapy, aiming to provide new hope for patients with unmet medical needs [7]